xiaolong liu

Dr. xiaolong liu

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2016 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
ZHZhenyue He
Zhenyue He
JYJun Yi
Jun Yi
XLxiaolong liu
xiaolong liu
JCJing Chen
Jing Chen
SHSiqi Han
Siqi Han
HSHaizhu Song
Haizhu Song
Background: Dysregulation of microRNAs (miRNAs) have been demonstrated to contribute to carcinogenesis. MiR-143-3p has been identified to function as a tumor suppressor in several tumors, but the role of miR-143-3p in esophageal squamous cell carcinoma (ESCC) has not been intensively investigated. Our aim was to evaluate the potential role of miR-143-3p in the progression of ESCC. Methods: The expression levels of miR-143-3p and QKI-5 protein were measured in 80 resected ESCC tumor specimens and the clinicopathological significance of these levels determined. We also investigated the role of miR-143-3p in the regulation of QKI-5 expression in ESCC cell lines both in vivo and in vitro. Results: MiR-143-3p levels were decreased in ESCC clinical samples and low expression of miR-143-3p was significantly associated with poor prognosis in ESCC patients. Ectopic expression of miR-143-3p suppressed proliferation and induced apoptosis in ESCC cells both in vivo and in vitro. Ectopic expression of miR-143-3p also reduced the metastatic potential of cells by selectively regulating epithelial–mesenchymal transition regulatory proteins. Furthermore, QKI-5 isoform was upregulated in ESCC tissues and was a direct target of miR-143-3p. Lastly, re-introduction of QKI-5 expression abrogated the inhibitory effects of miR-143-3p on ESCC cell proliferation and motility. Conclusions: Our results demonstrate that miR-143-3p acts as a tumor-suppressor by targeting QKI-5 in ESCC, suggesting that miR-143-3p is a potential therapy for the treatment of ESCC.

1 September 2020 in Radiology of Infectious Diseases
Verified
Journal Article
Open access
YZYue Zhao
Yue Zhao
XLxiaolong liu
xiaolong liu
WDWenshuai Duan
Wenshuai Duan
YLYiyang Liu
Yiyang Liu
WDWei Du
Wei Du
BYBin Yang
Bin Yang
This study aimed to investigate the atypical computed tomography (CT) presentations of coronavirus disease 2019 (COVID-19) patients to comprehensively understand this highly infectious disease. The clinical and chest CT imaging data of 16 patients diagnosed with COVID-19 were retrospectively analyzed, and patients with atypical CT presentations were selected for analysis and review. Of the 16 patients, 6 had atypical CT presentations, including 2 with faint ground glass opacities, 2 with single nodule, 1 with predominantly linear opacities, and 1 with predominantly reticular opacities. The dynamic changes of CT showed the faint ground glass opacities gradually became weak (2 cases). The scope of the single nodule was enlarged, and it developed into consolidation and residual fibrosis (2 cases). There was no obvious change of linear opacity (1 case). The reticular opacities were enlarged, then partially absorbed and new developed ground-glass opacities were found. Finally, the lesions were absorbed with residual fibrosis (1 case). Atypical CT presentations of COVID-19 can be classified as faint ground glass opacities, single nodule, linear opacities, and reticular opacities. Understanding the atypical presentation of COVID-19 is beneficial in the assessment and epidemic prevention and control of this disease.

29 September 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CSChen-Ye Shao
Chen-Ye Shao
JLJing Luo
Jing Luo
SJSheng Ju
Sheng Ju
CLChu-Ling Li
Chu-Ling Li
CDCheng Ding
Cheng Ding
LYLi-Qin Yang
Li-Qin Yang
Despite major advances in cancer therapeutics, the therapeutic options of Lung Squamous Cell Carcinoma (LSCC)-specific remain limited. Furthermore, the current staging system is imperfect for defining a prognosis and guiding treatment due to its simplicity and heterogeneity. We sought to develop prognostic decision tools for individualized survival prediction and treatment optimization in elderly patients with LSCC. Clinical data of 4564 patients (stageIB-IIIB) diagnosed from 2010 to 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database for prognostic nomograms development. The proposed models were externally validated using a separate group consisting of 1299 patients (stage IB-IIIB) diagnosed from 2012–2015 in China. The prognostic performance was measured using the concordance index (C-index), calibration curves, the average time-dependent area under the receiver operator characteristic curves (AUC), and decision curve analysis. Eleven candidate prognostic variables were identified by the univariable and multivariable Cox regression analysis. The calibration curves showed satisfactory agreement between the actual and nomogram-estimated Lung Cancer-Specific Survival (LCSS) rates. By calculating the c-indices and average AUC, our nomograms presented a higher prognostic accuracy than the current staging system. Clinical usefulness was revealed by the decision curve analysis. User-friendly online decision tools integrating proposed nomograms were created to estimate survival for patients with different treatment regimens. The decision tools for individualized survival prediction and treatment optimization might facilitate clinicians with decision-making, medical teaching, and experimental design. Online tools are expected to be integrated into clinical practice by using the freely available website (https://loyal-brand-611803.framer.app/).

11 November 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
TXTian Xie
Tian Xie
WHWei He
Wei He
ZLZhihao Li
Zhihao Li
HDHao Dong
Hao Dong
XLXingyi Li
Xingyi Li
YZYifan Zheng
Yifan Zheng
Introduction: Metastatic dissemination is a major determinant of poor outcome in lung adenocarcinoma (LUAD). However, molecular features associated with distinct metastatic states, particularly lymph node and brain metastases, remain incompletely defined. We investigated the relationship between HAX1 and LUAD metastatic progression. Methods: We reanalyzed publicly available single-cell RNA-sequencing data from GSE131907 to characterize HAX1 expression and associated transcriptional programs across normal lung, primary LUAD, advanced tumors, metastatic lymph nodes (mLN), and brain metastases. Findings were validated using additional public datasets from GEO and TCGA, including the independent single-cell dataset GSE69405. Clinical LUAD specimens were analyzed to assess HAX1 protein expression and its clinicopathological associations. Functional validation was performed in A549 and H1975 cells, and tumor growth was assessed using an A549-derived subcutaneous xenograft model. Results: HAX1 expression and the proportion of HAX1-positive epithelial cells increased across LUAD disease states and were significantly enriched in mLN and brain-metastatic epithelial populations compared with primary tumors. In a 125-patient clinical cohort, high HAX1 expression was associated with lymph node metastasis, advanced stage, and shorter overall survival, and remained independently associated with lymph node metastasis after adjustment for T stage (OR = 2.581, 95% CI 1.161–5.742; P = 0.020). An independent single-cell dataset further confirmed elevated HAX1 expression in brain-metastatic LUAD cells. HAX1-associated transcriptional programs converged on E2F, MYC, MTORC1, DNA replication, and cell-cycle signatures, whereas brain-metastatic epithelial cells additionally exhibited mitochondrial and translational programs. Integrated analyses identified UBE2S, PITX1, GGH, and PDCD2L as HAX1-associated candidates.EPIC and TIMER analyses consistently showed inverse correlations between HAX1 expression and estimated B-cell, CD4+ T-cell, CD8+ T-cell, and macrophage abundance. HAX1 knockdown also reduced cell viability, increased the G0/G1-phase fraction and decreased the S-phase fraction, reduced G1/S-related protein levels and PI3K/AKT signaling, and inhibited subcutaneous xenograft growth. Conclusion: HAX1 is closely associated with metastatic progression of LUAD, with strong clinical evidence for lymph node involvement and reproducible enrichment in brain-metastatic epithelial cells. Its associations with cell-cycle programs and immune cell infiltration, together with its functional role in G1/S progression, support further investigation of HAX1 in metastatic adaptation and tumor–immune interactions.